RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 21:32:43时区推断·⟳ 抓取 21:45:20·⚡ 决策 07-30 21:47:09 +1m49s·88.9 天前
强生Rybrevant Faspro头颈癌适应症获FDA优先审评
FDA授予Rybrevant Faspro补充BLA优先审评属于正向监管进展，但只是审评资格而非最终批准。
📄 原文RTTNews Biotech↗ 原文
Johnson & Johnson: FDA Grants Priority Review To SBLA For RYBREVANT FASPRO
Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian UK Wallst…
不做 强生（JNJ.US）
同一具体催化已在近72小时处理库命中为不做；且优先审评仅是程序性监管进展，对强生6178亿美元市值缺少可量化短线增量，不重复推卡。
不做 Genmab（GMAB.US）
虽可能有Rybrevant相关间接受益，但本条未披露Genmab的新增经济权益或销售增量，且同一催化已被系统处理，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 medium · price-in 风险 medium ↗
关键理由
- FDA授予Rybrevant Faspro补充BLA优先审评属于正向监管进展，但只是审评资格而非最终批准。
- 强生（JNJ.US）市值约6178亿美元，单一适应症审评进展相对公司体量不足以构成短线市值级增量。
- Genmab（GMAB.US）虽可能通过抗体技术/合作获得间接受益，但本条未披露新增经济权益或销售增量。
主要风险
- 本条已在近72小时处理库命中同一具体催化，不应重复推卡或重复建仓。
- 若后续FDA正式批准并披露可量化商业化增量，可由新事件重新评估。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部KB未命中与本次头颈癌优先审评直接相关的销售、权益或重大增量证据，命中多为无关报告。
检索:Rybrevant Faspro amivantamab head neck squamous cell carcinoma priority review JNJ Genmab royalty revenue sales - 做多前查反向 · 来源 search_processed_events · 日期 2026-07-30 · 影响 invalidates
已处理库命中同一具体催化且结论为不做，重复推送会打扰且不应再建新仓。
检索:search_processed_events hours=72 limit=200
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 7,039 字
Johnson & Johnson: FDA Grants Priority Review To SBLA For RYBREVANT FASPRO
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
Corporate News
By
RTTNews Staff Writer
✉
|
Published:
7/30/2026 9:32 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Johnson & Johnson (
JNJ
) announced that the FDA has granted Priority Review to the supplemental Biologics License Application for subcutaneous amivantamab and hyaluronidase-lpuj, or RYBREVANT FASPRO, for adults with recurrent or metastatic head and neck squamous cell carcinoma. The FDA's decision to grant Priority Review is supported by results from the Phase 1b/2 OrigAMI-4 study.
RYBREVANT FASPRO is approved in more than 40 countries, including the United States, Europe, and Japan, as a subcutaneous treatment for non-small cell lung cancer and continues to be evaluated in additional tumor types.
Johnson & Johnson shares are trading at $259.02 on NYSE, down 2.50 percent.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Latest Updates on Middle East War
U.S. Stocks May Regain Ground After Yesterday's Sell-Off
July 30, 2026 08:57 ET
US Intensifies Attacks On Iran In Retaliation
July 30, 2026 06:00 ET
U.S. Dollar Slides As Fed Holds Interest Rates Amid Renewed Middle East Conflict
July 29, 2026 17:00 ET
Canadian Stocks Tumble Amid Fresh U.S.-Iran Escalation, Fed Interest Rate Decision
July 29, 2026 16:35 ET
Crude Oil Skyrockets After Iran Targets Jordan, U.S.-Saudi Forces Hit Iraq
July 29, 2026 14:38 ET
View More
FDA Decisions August 2026: Key PDUFA Dates Biotech Investors Are Watching | RTT BIOTECH NEWS
July 30, 2026 04:24 ET
The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment.
In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
View More Videos
RELATED NEWS
J&J Strikes $3.51 Bln Deal With Sail To Develop In-Vivo CAR-T Therapies For Immune Diseases
Johnson & Johnson Strikes $5.5 Bln Talc Settlement Deal, Subject To 95% Claimant Approval
J&J's Tecvayli, Talvey Combinations Improve PFS In Phase 3 Multiple Myeloma Trial
J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trial
Johnson & Johnson Wins FDA Authorization For OTTAVA Robotic Surgical System
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
Editor's Pick
Most Read
Most Emailed
Xerox Stock Up 26% On Q2 Turnaround, Raised FY26 Outlook
July 30, 2026 08:42 ET
Automatic Data Processing Sees Growth In FY27 - Update
July 29, 2026 07:20 ET
GE HealthCare Stock Up 13% On Strong Q2 Profit & Orders, Positive Outlook
Boston Scientific Trims FY26 Outlook - Update
July 29, 2026 06:50 ET
Humana Q2 Profit Climbs, Cuts FY26 EPS Outlook, Backs Adj. Earnings, Revenue View; Stock Down
July 29, 2026 06:44 ET
Boeing Q4 Net Loss Narrows, Revenues Rise 8%
July 28, 2026 08:03 ET
Coca-Cola Boosts FY26 Outlook - Update
July 28, 2026 07:24 ET
UPS Lifts FY26 Outlook, Despite Weak Q2 Profit
July 28, 2026 07:09 ET
Philips Stock Drops On Weak Q2 Orders, Despite Profit Growth, Positive Outlook
July 28, 2026 06:01 ET
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
July 27, 2026 04:19 ET
Ecolab Raises 2026 Earnings Guidance
July 28, 2026 08:33 ET
Expand Energy To Buy Twin Eagle For $1.25 Bln
July 27, 2026 07:49 ET
ProStar Holdings Appoints Michael Wolff As CEO, Succeeding Founder Page Tucker; Shares Down
July 27, 2026 08:34 ET
Carpenter Technology CEO Brian Malloy Passes Away; Tony Thene Named CEO
July 27, 2026 08:18 ET
Argenx To Buy Forte Biosciences In Around $2.2 Bln Cash Deal; Forte Biosciences Shares Climb
July 27, 2026 01:24 ET
Virtuix Says Tesla Buys Simulation System For Optimus Robots; Shares Tumble
July 27, 2026 11:17 ET
Luxfer Holdings To Be Bought By Wynnchurch Capital For $17.37/Share
July 27, 2026 08:51 ET
HYBE Q2 Earnings Jumps; Shares Fall 9%
July 28, 2026 02:05 ET
Siemens, NVIDIA Expand Partnership To Boost AI-Powered EDA
July 27, 2026 01:46 ET
Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook
July 30, 2026 02:02 ET
Perfect Corp. Q2 Profit Climbs
July 27, 2026 06:39 ET
SK Group And NVIDIA Expand $500 Bln+ AI Factories And Memory Partnership
July 25, 2026 01:30 ET
Rocket Lab Awarded $266 Mln Multi-launch Contract With U.S. Space Force, Shares Up
July 27, 2026 06:46 ET
NAVER, NVIDIA And Brookfield Plan 200MW Expansion Of Korea's AI Factory Infrastructure
July 25, 2026 01:52 ET
Bank Of Hawaii Corporation Profit Rises In Q2
July 27, 2026 06:56 ET
Microchip Technology To Acquire Hailo
July 25, 2026 02:16 ET
First Farmers And Merchants Corporation Reports Increase In Q2 Profit
July 27, 2026 07:07 ET
Kuwait Oil Co. Signs $16 Bln Pipeline Infrastructure Partnership With Blackstone, Brookfield And KKR
July 25, 2026 02:42 ET
HBT Financial, Inc. Q2 Income Advances
July 27, 2026 07:14 ET
Trip.com Fined By SAMR For Online Hotel Booking Abuses
July 25, 2026 06:18 ET
Lakeland Financial Corp. Reports Rise In Q2 Profit
July 27, 2026 07:21 ET
Everbright Digital Prices Public Offering Of 4.293 Mln Ordinary Shares At $1.88/Shr
July 26, 2026 12:05 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
Corporate News
By
RTTNews Staff Writer
✉
|
Published:
7/30/2026 9:32 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Johnson & Johnson (
JNJ
) announced that the FDA has granted Priority Review to the supplemental Biologics License Application for subcutaneous amivantamab and hyaluronidase-lpuj, or RYBREVANT FASPRO, for adults with recurrent or metastatic head and neck squamous cell carcinoma. The FDA's decision to grant Priority Review is supported by results from the Phase 1b/2 OrigAMI-4 study.
RYBREVANT FASPRO is approved in more than 40 countries, including the United States, Europe, and Japan, as a subcutaneous treatment for non-small cell lung cancer and continues to be evaluated in additional tumor types.
Johnson & Johnson shares are trading at $259.02 on NYSE, down 2.50 percent.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Latest Updates on Middle East War
U.S. Stocks May Regain Ground After Yesterday's Sell-Off
July 30, 2026 08:57 ET
US Intensifies Attacks On Iran In Retaliation
July 30, 2026 06:00 ET
U.S. Dollar Slides As Fed Holds Interest Rates Amid Renewed Middle East Conflict
July 29, 2026 17:00 ET
Canadian Stocks Tumble Amid Fresh U.S.-Iran Escalation, Fed Interest Rate Decision
July 29, 2026 16:35 ET
Crude Oil Skyrockets After Iran Targets Jordan, U.S.-Saudi Forces Hit Iraq
July 29, 2026 14:38 ET
View More
FDA Decisions August 2026: Key PDUFA Dates Biotech Investors Are Watching | RTT BIOTECH NEWS
July 30, 2026 04:24 ET
The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment.
In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
View More Videos
RELATED NEWS
J&J Strikes $3.51 Bln Deal With Sail To Develop In-Vivo CAR-T Therapies For Immune Diseases
Johnson & Johnson Strikes $5.5 Bln Talc Settlement Deal, Subject To 95% Claimant Approval
J&J's Tecvayli, Talvey Combinations Improve PFS In Phase 3 Multiple Myeloma Trial
J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trial
Johnson & Johnson Wins FDA Authorization For OTTAVA Robotic Surgical System
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
Editor's Pick
Most Read
Most Emailed
Xerox Stock Up 26% On Q2 Turnaround, Raised FY26 Outlook
July 30, 2026 08:42 ET
Automatic Data Processing Sees Growth In FY27 - Update
July 29, 2026 07:20 ET
GE HealthCare Stock Up 13% On Strong Q2 Profit & Orders, Positive Outlook
Boston Scientific Trims FY26 Outlook - Update
July 29, 2026 06:50 ET
Humana Q2 Profit Climbs, Cuts FY26 EPS Outlook, Backs Adj. Earnings, Revenue View; Stock Down
July 29, 2026 06:44 ET
Boeing Q4 Net Loss Narrows, Revenues Rise 8%
July 28, 2026 08:03 ET
Coca-Cola Boosts FY26 Outlook - Update
July 28, 2026 07:24 ET
UPS Lifts FY26 Outlook, Despite Weak Q2 Profit
July 28, 2026 07:09 ET
Philips Stock Drops On Weak Q2 Orders, Despite Profit Growth, Positive Outlook
July 28, 2026 06:01 ET
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
July 27, 2026 04:19 ET
Ecolab Raises 2026 Earnings Guidance
July 28, 2026 08:33 ET
Expand Energy To Buy Twin Eagle For $1.25 Bln
July 27, 2026 07:49 ET
ProStar Holdings Appoints Michael Wolff As CEO, Succeeding Founder Page Tucker; Shares Down
July 27, 2026 08:34 ET
Carpenter Technology CEO Brian Malloy Passes Away; Tony Thene Named CEO
July 27, 2026 08:18 ET
Argenx To Buy Forte Biosciences In Around $2.2 Bln Cash Deal; Forte Biosciences Shares Climb
July 27, 2026 01:24 ET
Virtuix Says Tesla Buys Simulation System For Optimus Robots; Shares Tumble
July 27, 2026 11:17 ET
Luxfer Holdings To Be Bought By Wynnchurch Capital For $17.37/Share
July 27, 2026 08:51 ET
HYBE Q2 Earnings Jumps; Shares Fall 9%
July 28, 2026 02:05 ET
Siemens, NVIDIA Expand Partnership To Boost AI-Powered EDA
July 27, 2026 01:46 ET
Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook
July 30, 2026 02:02 ET
Perfect Corp. Q2 Profit Climbs
July 27, 2026 06:39 ET
SK Group And NVIDIA Expand $500 Bln+ AI Factories And Memory Partnership
July 25, 2026 01:30 ET
Rocket Lab Awarded $266 Mln Multi-launch Contract With U.S. Space Force, Shares Up
July 27, 2026 06:46 ET
NAVER, NVIDIA And Brookfield Plan 200MW Expansion Of Korea's AI Factory Infrastructure
July 25, 2026 01:52 ET
Bank Of Hawaii Corporation Profit Rises In Q2
July 27, 2026 06:56 ET
Microchip Technology To Acquire Hailo
July 25, 2026 02:16 ET
First Farmers And Merchants Corporation Reports Increase In Q2 Profit
July 27, 2026 07:07 ET
Kuwait Oil Co. Signs $16 Bln Pipeline Infrastructure Partnership With Blackstone, Brookfield And KKR
July 25, 2026 02:42 ET
HBT Financial, Inc. Q2 Income Advances
July 27, 2026 07:14 ET
Trip.com Fined By SAMR For Online Hotel Booking Abuses
July 25, 2026 06:18 ET
Lakeland Financial Corp. Reports Rise In Q2 Profit
July 27, 2026 07:21 ET
Everbright Digital Prices Public Offering Of 4.293 Mln Ordinary Shares At $1.88/Shr
July 26, 2026 12:05 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。